Grade My Investments
HomeFree Stock Grades › OABI

OmniAb, Inc. (OABI) Stock Grade

OABI · Healthcare

C+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$210.2M
P/E Ratio
Revenue Growth (YoY)
-29.3%
Net Margin
-347.0%
Return on Equity
Dividend Yield
None

About OmniAb, Inc.'s fundamentals

OmniAb is a biotechnology company with a market capitalization of $210.2 million that is currently unprofitable, with a net loss in its latest annual statement and a net margin of -347.0%. The company experienced significant revenue contraction, declining 29.3% year-over-year, indicating weakening commercial traction. With no dividend yield and negative profitability metrics, the company is in a capital-intensive development phase dependent on future revenue growth and operational improvements to achieve positive returns.

Track OABI free — no credit card required. Live grade + monthly AI report →